The Manufacturers Life Insurance Company Purchases 18,427 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

The Manufacturers Life Insurance Company grew its position in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 19.1% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 114,814 shares of the company’s stock after purchasing an additional 18,427 shares during the period. The Manufacturers Life Insurance Company owned approximately 0.16% of Structure Therapeutics worth $5,534,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in GPCR. Sterling Capital Management LLC purchased a new stake in shares of Structure Therapeutics in the first quarter worth $28,000. State of Wyoming bought a new stake in Structure Therapeutics during the second quarter valued at $28,000. CWM LLC grew its position in Structure Therapeutics by 35.2% during the fourth quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after buying an additional 125 shares in the last quarter. Assetmark Inc. grew its position in Structure Therapeutics by 21.4% during the first quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock worth $123,000 after buying an additional 449 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey bought a new position in Structure Therapeutics in the 4th quarter worth about $127,000. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Structure Therapeutics Stock Up 1.6%

Shares of GPCR stock opened at $50.42 on Thursday. The business has a 50-day moving average price of $47.11 and a two-hundred day moving average price of $54.45. Structure Therapeutics Inc. Sponsored ADR has a 12-month low of $15.80 and a 12-month high of $94.90. The firm has a market cap of $3.58 billion, a P/E ratio of -57.95 and a beta of -1.43.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.04. As a group, research analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -1.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

GPCR has been the subject of a number of research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Friday, July 17th. Canaccord Genuity Group assumed coverage on shares of Structure Therapeutics in a research report on Monday, April 27th. They issued a “buy” rating and a $101.00 price objective on the stock. Wall Street Zen raised shares of Structure Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. Finally, HC Wainwright dropped their target price on shares of Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research report on Thursday, June 11th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $110.55.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.